These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 11823041)

  • 1. Efficacy and safety of CD34-selected and CD19-depleted autografting in multiple myeloma patients: a pilot study.
    Rasmussen T; Björkstrand B; Andersen H; Gaarsdal E; Johnsen HE
    Exp Hematol; 2002 Jan; 30(1):82-8. PubMed ID: 11823041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selection and transplantation of autologous CD34+ B-lineage negative cells in advanced-phase multiple myeloma patients: a pilot study.
    Lemoli RM; Martinelli G; Olivieri A; Motta MR; Rizzi S; Terragna C; Leopardi G; Benni M; Ronconi S; Cantori I; Rondelli D; Mangianti S; Leoni P; Montanari M; Cavo M; Tura S
    Br J Haematol; 1999 Nov; 107(2):419-28. PubMed ID: 10583236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autologous transplantation of mobilized peripheral blood CD34+ cells selected by immunomagnetic procedures in patients with multiple myeloma.
    Abonour R; Scott KM; Kunkel LA; Robertson MJ; Hromas R; Graves V; Lazaridis EN; Cripe L; Gharpure V; Traycoff CM; Mills B; Srour EF; Cornetta K
    Bone Marrow Transplant; 1998 Nov; 22(10):957-63. PubMed ID: 9849692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
    Lemoli RM; Cavo M; Fortuna A
    J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selection and transplantation of autologous hematopoietic CD34+ cells for patients with multiple myeloma.
    Lemoli RM; Fortuna A; Raspadori D; Ventura MA; Martinelli G; Gozzetti A; Leopardi G; Ratta M; Cavo M; Tura S
    Leuk Lymphoma; 1997 Dec; 26 Suppl 1():1-11. PubMed ID: 9570675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clonotypic myeloma cells able to xenograft myeloma to nonobese diabetic severe combined immunodeficient mice copurify with CD34 (+) hematopoietic progenitors.
    Pilarski LM; Belch AR
    Clin Cancer Res; 2002 Oct; 8(10):3198-204. PubMed ID: 12374689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD34+ subset and tumor cell quantitation by flow cytometry--step toward quality assessment of autografts in B cell malignancies.
    Johnsen HE; Rasmussen T; Knudsen LM
    Vox Sang; 1998; 74 Suppl 2():477-82. PubMed ID: 9704485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined positive/negative purging and transplantation of peripheral blood progenitor cell autografts in breast cancer patients: a pilot study.
    Mapara MY; Körner IJ; Lentzsch S; Krahl D; Reichardt P; Dörken B
    Exp Hematol; 1999 Jan; 27(1):169-75. PubMed ID: 9923456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD34+-enriched-CD19+-depleted autologous peripheral blood stem cell transplantation for chronic lymphoproliferative disorders: high purging efficiency but increased risk of severe infections.
    Altès A; Sierra J; Esteve J; Martín-Henao G; Marín P; Sureda A; Briones J; Martino R; Villamor N; Colomer D; Carreras E; Garcia J; Brunet S; Montserrat E
    Exp Hematol; 2002 Jul; 30(7):824-30. PubMed ID: 12135682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of simultaneous immunomagnetic CD34+ cell selection and breast cancer cell purging in peripheral blood progenitor cell samples used for hematopoietic rescue after high-dose therapy.
    Mohr M; Hilgenfeld E; Fietz T; Hoppe B; Koenigsmann M; Hoffmann M; Knauf WU; Cassens U; Sibrowski W; Kienast J; Thiel E; Berdel WE
    Clin Cancer Res; 1999 May; 5(5):1035-40. PubMed ID: 10353736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transplantation with selected autologous peripheral blood CD34+Thy1+ hematopoietic stem cells (HSCs) in multiple myeloma: impact of HSC dose on engraftment, safety, and immune reconstitution.
    Michallet M; Philip T; Philip I; Godinot H; Sebban C; Salles G; Thiebaut A; Biron P; Lopez F; Mazars P; Roubi N; Leemhuis T; Hanania E; Reading C; Fine G; Atkinson K; Juttner C; Coiffier B; Fière D; Archimbaud E
    Exp Hematol; 2000 Jul; 28(7):858-70. PubMed ID: 10907648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low efficiency of a newly introduced high-density microparticles method for B cell depletion in multiple myeloma patients undergoing autologous hematopoietic stem cell transplantation.
    Perseghin P; Dassi M; Belotti D; Pioltelli P; Pogliani EM
    J Hematother Stem Cell Res; 2003 Oct; 12(5):537-41. PubMed ID: 14594510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Purging of peripheral blood stem cells yields BCR-ABL-negative autografts in patients with BCR-ABL-positive acute lymphoblastic leukemia.
    Martin H; Atta J; Zumpe P; Eder M; Elsner S; Rode C; Wassmann B; Bruecher J; Hoelzer D
    Exp Hematol; 1995 Dec; 23(14):1612-8. PubMed ID: 8542955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor cell depletion of peripheral blood progenitor cells using positive and positive/negative selection in metastatic breast cancer.
    Preti RA; Lazarus HM; Winter J; Stadtmauer EA; Nadasi S; McMannis J; Karandish S; Jennis A; Goldberg SL; Pecora AL
    Cytotherapy; 2001; 3(2):85-95. PubMed ID: 12028831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positive selection and transplantation of autologous highly purified CD133(+) stem cells in resistant/relapsed chronic lymphocytic leukemia patients results in rapid hematopoietic reconstitution without an adequate leukemic cell purging.
    Isidori A; Motta MR; Tani M; Terragna C; Zinzani P; Curti A; Rizzi S; Taioli S; Giudice V; D'Addio A; Gugliotta G; Conte R; Baccarani M; Lemoli RM
    Biol Blood Marrow Transplant; 2007 Oct; 13(10):1224-32. PubMed ID: 17889360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined positive/negative selection for highly effective purging of PBPC grafts: towards clinical application in patients with B-CLL.
    Paulus U; Schmitz N; Viehmann K; von Neuhoff N; Dreger P
    Bone Marrow Transplant; 1997 Sep; 20(5):415-20. PubMed ID: 9339759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicenter phase III trial to evaluate CD34(+) selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma.
    Vescio R; Schiller G; Stewart AK; Ballester O; Noga S; Rugo H; Freytes C; Stadtmauer E; Tarantolo S; Sahebi F; Stiff P; Meharchard J; Schlossman R; Brown R; Tully H; Benyunes M; Jacobs C; Berenson R; DiPersio J; Anderson K; Berenson J
    Blood; 1999 Mar; 93(6):1858-68. PubMed ID: 10068658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD34+ selection of autologous peripheral blood stem cells for transplantation following sequential cycles of high-dose therapy and mobilization in multiple myeloma.
    Dyson PG; Horvath N; Joshua D; Barrow L; Van Holst NG; Brown R; Gibson J; To LB
    Bone Marrow Transplant; 2000 Jun; 25(11):1175-84. PubMed ID: 10849530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined isolation of CD34+ progenitor cells and reduction of B cells from peripheral blood by use of immunomagnetic methods.
    Martín-Henao GA; Picón M; Rueda F; Amill B; Querol S; Gonzalez-Barca E; Ferrá C; Grañena A; García J
    Transfusion; 2002 Jul; 42(7):912-20. PubMed ID: 12375665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CXCR4 expression on transplanted peripheral blood CD34+ cells: relationship to engraftment after autologous transplantation in a cohort of multiple myeloma patients.
    Hicks C; Isaacs A; Wong R; Chong BH
    Ann Hematol; 2011 May; 90(5):547-55. PubMed ID: 20957366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.